Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Account Payables: 2018-2024

Historic Change in Account Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$503,000.

  • Allogene Therapeutics' Change in Account Payables rose 85.17% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 114.06%. This contributed to the annual value of -$503,000 for FY2024, which is 93.30% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Change in Account Payables of -$503,000 as of FY2024, which was up 93.30% from -$7.5 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Change in Account Payables peaked at $4.9 million during FY2022, and registered a low of -$7.5 million during FY2023.
  • Its 3-year average for Change in Account Payables is -$1.0 million, with a median of -$503,000 in 2024.
  • Per our database at Business Quant, Allogene Therapeutics' Change in Account Payables soared by 734.68% in 2022 and then slumped by 254.11% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Change in Account Payables (Yearly) stood at $615,000 in 2020, then tumbled by 224.72% to -$767,000 in 2021, then skyrocketed by 734.68% to $4.9 million in 2022, then tumbled by 254.11% to -$7.5 million in 2023, then surged by 93.30% to -$503,000 in 2024.